{"denoms":[{"counts":[{"groupId":"BG000","value":"77"}],"units":"Participants"}],"groups":[{"description":"Ann Arbor stage IIB, IIIB, IVA, or IVB participants receive:\n\n2 cycles of AEPA chemotherapy:\n\n(A) Brentuximab vedotin 1.2 mg/kg IV (intravenous) days 1, 8 and 15, (E) Etoposide 125 mg/m\\^2 IV days 1-5, (P) Prednisone 60 mg/m\\^2/day PO (orally) days 1-15, (A) Doxorubicin 40 mg/m\\^2 IV days 1 and 15),\n\nFollowed by 4 cycles of CAPDac:\n\n(C) Cyclophosphamide 500 mg/m\\^2 IV days 1 and 8, (A) Brentuximab vedotin 1.2 mg/kg IV days 1 and 8, (P) Prednisone 40 mg/m\\^2/day PO days 1-15, (Dac) Dacarbazine 250 mg/m\\^2 IV days 1-3.).\n\nFilgrastim 5 mcg/kg subcutaneous (SC) as clinically indicated.\n\nFor those with lymph nodes that do not go into remission after 2 courses of AEPA chemotherapy, radiation therapy is given.","id":"BG000","title":"AEPA/CAPDac"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"6","upperLimit":"19","value":"16"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"39"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"38"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}]}],"title":"Asian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"17"}]}],"title":"Black or African American"},{"categories":[{"measurements":[{"groupId":"BG000","value":"50"}]}],"title":"White"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}]}],"title":"More than one race"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"Others"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"59"}],"title":"St. Jude Children's Research Hospital"},{"measurements":[{"groupId":"BG000","value":"9"}],"title":"Stanford University Medical Center"},{"measurements":[{"groupId":"BG000","value":"4"}],"title":"Dana Farber Cancer Institute"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Maine Medical Center"},{"measurements":[{"groupId":"BG000","value":"2"}],"title":"Massachusetts General Hospital"},{"measurements":[{"groupId":"BG000","value":"2"}],"title":"St. Jude Midwest Affiliate"}],"title":"United States"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Region of Enrollment","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"59"}]}],"title":"Nodular sclerosing"},{"categories":[{"measurements":[{"groupId":"BG000","value":"11"}]}],"title":"Classical, NOS"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}]}],"title":"Lymphocyte rich"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}],"title":"Mixed cellularity"}],"description":"Abbreviation: NOS, not otherwise specified.","paramType":"COUNT_OF_PARTICIPANTS","title":"Histology","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"13"}]}],"title":"IIB"},{"categories":[{"measurements":[{"groupId":"BG000","value":"19"}]}],"title":"IIIB"},{"categories":[{"measurements":[{"groupId":"BG000","value":"12"}]}],"title":"IVA"},{"categories":[{"measurements":[{"groupId":"BG000","value":"33"}]}],"title":"IVB"}],"description":"II: Involvement of 2 or more lymph node regions on the same side of the diaphragm (II) or localized contiguous involvement of a single extra-lymphatic organ or site and its regional lymph node(s) III: Involvement of lymph node regions on both sides of the diaphragm (III), which may also be accompanied by localized contiguous involvement of an extra-lymphatic organ or site (IIIE) IV: Disseminated (multifocal) involvement of 1 or more extra-lymphatic organs or tissues, with/without associated lymph node involvement, or isolated extra-lymphatic organ involvement with distant nodal involvement","paramType":"COUNT_OF_PARTICIPANTS","title":"Stage","unitOfMeasure":"Participants"}],"populationDescription":"For staging: B symptoms (unexplained fevers, drenching night sweats or \\> 10% weight loss). A= absence of B symptoms"}